Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32044
Title: Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Austin Authors: Walpole, Imogen;Lee, Belinda;Shapiro, Jeremy;Thomson, Benjamin;Lipton, Lara;Ananda, Sumitra;Usatoff, Val;Mclachlan, Sue-Ann;Knowles, Brett;Fox, Adrian;Wong, Rachel;Cooray, Prasad;Burge, Matthew;Clarke, Kate;Pattison, Sharon;Nikfarjam, Mehrdad ;Tebbutt, Niall C ;Harris, Marion;Nagrial, Adnan;Zielinski, Rob;Chee, Cheng Ean;Gibbs, Peter
Affiliation: Department of Medical Oncology, Northern Hospital, Victoria, Australia.
Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia.
Department of Medical Oncology, Cabrini Health, Malvern, Victoria, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia.
Faculty of Medicine & Health Sciences, Faculty fo Medicine University of Melbourne, Victoria, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia.
Department of Medical Oncology, St Vincent's Hospital, Victoria, Australia.
Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
Department of Medical Oncology, Knox Private Hospital, Victoria, Australia.
Department of Medical Oncology, Royal Brisbane Hospital, Queensland, Australia.
Department of Medical Oncology, Wellington Hospital, Wellington, New Zealand.
Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Faculty of Medicine & Health Sciences, Faculty fo Medicine University of Melbourne, Victoria, Australia.
Medical Oncology
Department of Medical Oncology, Monash Medical Centre, Victoria, Australia.
Department of Medical Oncology, Westmead Hospital, New South Wales, Australia.
Department of Medical Oncology, Orange Hospital, New South Wales, Australia.
Department of Medical Oncology, National University Cancer Institute, Singapore.
Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
Issue Date: Feb-2023
metadata.dc.date: 2022
Publication information: Asia-Pacific Journal of Clinical Oncology 2023; 19(1)
Abstract: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable METHOD: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and March 2019 within the Australasian Pancreatic Cancer Registry (PURPLE, Pancreatic cancer: Understanding Routine Practice and Lifting End results) was performed. Clinicopathological characteristics, treatment, and outcome were analyzed. Overall survival (OS) comparison was performed using log-rank model and Kaplan-Meier analysis.
URI: https://ahro.austin.org.au/austinjspui/handle/1/32044
DOI: 10.1111/ajco.13807
ORCID: 
Journal: Asia-Pacific Journal of Clinical Oncology
Start page: 214
End page: 225
PubMed URL: 35831999
ISSN: 1743-7563
Type: Journal Article
Subjects: drug therapy
general surgery
mortality
neoadjuvant therapy
pancreatic neoplasms
Pancreatic Neoplasms/drug therapy
Pancreatic Neoplasms/surgery
Pancreatic Neoplasms/pathology
Neoadjuvant Therapy/methods
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Carcinoma, Pancreatic Ductal/drug therapy
Carcinoma, Pancreatic Ductal/surgery
Carcinoma, Pancreatic Ductal/pathology
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Jan 31, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.